Answer:
Phase III
Explanation:
The given condition fall in the trial phase (Phase III) of cinical study which aims to:
- Determine drug's effectiveness (primary goal)
- Determine long-term drug safety
- Confirm findings
In Phase III, randomised, double-blind, placebo-controlled, parallel group study is majorly to evaluate the efficacy and safety of placebo in episodic migraine prevention in children (6 to < 12 years of age) and adolescents (12 to < 18 years of age).
The trial consists of four phases: screening; double-blind therapy period for 24 weeks in which placebo or Erenumab is given to subject as dose 1, dose 2 or dose 3 (based on the participant's body weight) once a month via subcutaneous injection; optional dose level blinded extension phase (40 weeks) which involves subjects recieve dose1, 2 and 3 of placebo, and at last it follows a safety follow-up phase for 12 weeks (after 16 weeks of the last dose of investigational drug).
Hence, the clinical phase is phase III.
Answer:
Potential Energy and Kinetic Energy
There’s no image attached to this question
Answer:
Two recessive genes for attached earlobes
Explanation:
For a recessive trait to be displayed, it must mean that the individual does not possess a dominant allele that would be expressed instead of the recessive allele. Therefore, Ashley must have two copies of the recessive genes to have attached earlobes. Possessing one or two dominant genes for free earlobes would mean that she would have free earlobes.
This can also be visualised with a punnet square, see attached image. We know the parents carry a recessive allele but have free earlobes, so they must have the genotype Ff. The punnet square shows 3 genotypes are possible
FF, which would give free ear lobes
Ff, the same genotype as her parents, free earlobes
and ff, which would give attached earlobes.
Nature not sure how to explain so sorry
